AR Solutions In Action

FISCAL YEAR 2023

CDC's Investments to Combat Antimicrobial Resistance Threats

NEW JERSEY \$1,042,685

Funding for AR Activities Fiscal Year 2023

FUNDING TO HEALTH DEPARTMENTS

Rapid Detection & Response: State, territory, and local public health partners fight AR in health care, the community, and food.

\$919,128

CDC-funded HAI/AR Programs form a network of health departments that detect, prevent, respond to, and contain HAI/AR threats and promote appropriate use of antibiotics and antifungals. CDC's AR Lab Network provides nationwide lab capacity to rapidly detect AR and inform local prevention and response activities to stop the spread of antimicrobial-resistant germs and protect people.



\$104.807

Food Safety projects protect communities by rapidly identifying antimicrobial-resistant foodborne bacteria to stop and solve outbreaks and improve prevention.

New Jersey uses whole genome sequencing to track local outbreaks of *Listeria*, *Salmonella*, *Campylobacter*, *Shigella*, and *Escherichia coli*, identifies AR genes, and shares surveillance data with PulseNet. When outbreaks are detected, local CDC-supported epidemiologists respond to stop their spread.



\$15,000

Drug-resistant Gonorrhea Detect & Respond Program works with state and local epidemiology and laboratory partners to test for and quickly respond to resistant gonorrhea to stop its spread in high-risk communities. Only one recommended treatment option remains for gonorrhea and resistance to other antibiotics continues to grow. The Gonococcal Isolate Surveillance Project (GISP) informs national treatment guidelines for gonorrhea by monitoring how well antibiotics work on laboratory samples collected from sentinel STD clinics, which often are the first to detect the threat. Select STD clinics also enhance surveillance by collecting additional gonococcal isolates from women and from extragenital sites. This work is jointly supported by CDC STI and AR funds.

The AR Investment Map includes data from CDC's largest funding categories for AR. It represents extramural funding that supports AR activities from multiple funding lines in CDC's annual appropriations. Some work received full or partial funding from one-time supplemental appropriations. See the fiscal year 2023 AR Investment Map Supplemental Funding Fact Sheet for more information.

AR: antimicrobial resistance
COVID-19: coronavirus disease 2019
HAI: healthcare-associated infection
IPC: infection prevention and control

NHSN: National Healthcare Safety Network STD: sexually transmitted disease

STI: sexually transmitted infection

Page 1 of 2

CDC provides critical support in the U.S. and abroad to protect people from antimicrobial resistance.



AR Solutions In Action

FISCAL YEAR

2023

CDC's Investments to Combat Antimicrobial Resistance Threats

NEW JERSEY - AR Investments (cont.)

FUNDING TO UNIVERSITIES & HEALTHCARE PARTNERS



\$3,750

Global Tuberculosis Institute at Rutgers, The State University of New Jersey: Innovative Prevention & Tracking CDC's Tuberculosis (TB) Centers of Excellence for Training, Education, and Medical Consultation (COEs) increase knowledge, skills, and abilities for TB prevention and control through communication, education, and training activities. The COEs also improve sustainable evidence-based TB clinical practices and patient care through the provision of expert medical consultation.

The AR Investment Map includes data from CDC's largest funding categories for AR. It represents extramural funding that supports AR activities from multiple funding lines in CDC's annual appropriations. Some work received full or partial funding from one-time supplemental appropriations. See the fiscal year 2023 AR Investment Map Supplemental Funding Fact Sheet for more information.

AR: antimicrobial resistance
COVID-19: coronavirus disease 2019
HAI: healthcare-associated infection
IPC: infection prevention and control

NHSN: National Healthcare Safety Network STD: sexually transmitted disease

STI: sexually transmitted infection

Page 2 of 2

CDC provides critical support in the U.S. and abroad to protect people from antimicrobial resistance.

